文献速递淋巴瘤

如何管理外周T细胞淋巴瘤非特指型与血管免疫母细胞性T细胞淋巴瘤:当前实践与未来展望

How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
PubMed 文献 · Br J Haematol · 2016-12-16

本文综述外周T细胞淋巴瘤非特指型(PTCL-NOS)与血管免疫母细胞性T细胞淋巴瘤(AITL)的当前管理实践。CHO(E)P仍为一线标准治疗,缓解者行自体干细胞移植,约50%患者可长期生存;复发难治者预后差,挽救性吉西他滨治疗后尽可能行异基因移植。新药II期研究缓解率10%–30%,长期缓解罕见。

要点

  • CHO(E)P仍为PTCL-NOS与AITL的一线标准治疗。
  • 无合并症且达完全或部分缓解者行自体干细胞移植,约50%可长期生存。
  • 一线治疗后复发或进展者预后差,挽救性吉西他滨治疗后尽可能行异基因移植。

核心结论

  • PTCL-NOS与AITL是最常见的成熟PTCL亚型,尽管对其(表观)遗传学背景的认识有进展,治疗进展有限,CHO(E)P仍为一线标准治疗。
  • 新药II期研究缓解率10%–30%,长期缓解属例外,多数新药未获批且不易获得,大量靶向(表观)遗传异常的创新药物处于早期开发阶段。

研究设计与样本

  • 本文为综述,汇总PTCL-NOS与AITL当前实践与未来方向,未报告检索范围。

主要发现

  • 无合并症且达完全或部分缓解的患者接受自体干细胞移植,约50%患者长期生存。
  • 一线治疗后复发或进展的患者预后差,接受挽救性吉西他滨治疗,并尽可能行异基因移植。
  • 异基因移植后约半数患者长期生存,其他任何治疗均为姑息性。
  • II期研究中的新药缓解率为10%–30%,长期缓解属例外。

临床怎么用

  • CHO(E)P仍为一线标准治疗。
  • 无合并症且达完全或部分缓解者行自体干细胞移植。
  • 一线治疗后复发或进展者接受挽救性吉西他滨治疗,并尽可能行异基因移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphoma (PTCL), not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma (AITL) are the most frequent of more than 20 mature PTCL entities featuring a broad spectrum of morphological, immunophenotypic, molecular and clinical characteristics. Unfortunately, recent progress in understanding the (epi)genetic background of PTCL has not been met with similar advances in treatment. Thus, CHO(E)P [cyclophosphamide, doxorubicin, vincristine, and prednisone (plus etoposide)] remains standard first-line therapy. Patients without comorbidities achieving complete or partial remission proceed to autologous stem cell transplantation. With this approach about 50% of patients survive long-term. Patients relapsing after or progressing during first-line therapy have a dismal prognosis. They receive salvage gemcitabine-therapy followed by allogeneic transplantation whenever possible. After allografting, approximately half of the patients survive long-term; any other treatment is palliative. New drugs investigated in phase II studies achieved response rates between 10% and 30%; long-term remissions are the exception to the rule. While most new drugs are not licensed and not readily available, a plethora of other innovative drugs targeting (epi-)genetic abnormalities are in early development. These, together with combinations of new and old drugs, will hopefully increase response to first-line therapy, bridge more patients to transplantation, and finally improve prognosis for all patients with PTCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2016. PMID: 27982416. doi:10.1111/bjh.14473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。